A systematic review of the effectiveness of adalimumab

tumor necrosis factor therapy in the clinic. Arthritis
Rheum 2005;52:3873–9.
94. Gomez-Puerta JA, Rodriguez-Cros JR, Graell E,
Cañete JD, Albaladejo C, Sanmarti R. One-year
efficacy of etanercept in rheumatoid arthritis
patients who previously failed to infliximab.
Arthritis Rheum 2004;50(Suppl):S190.
95. Keystone EC, Perruquet JL, Lidman RW, Stein B,
Peller JS, Xia HA, et al. Switching anti-TNF
therapy: real-world outcome of patients with
rheumatoid arthritis who failed either infliximab
or etanercept treatment and switched to another
TNF inhibitor. Arthritis Rheum 2004;50(Suppl):
S400–1.
96. Westhovens R, Wolfe F, Rahman MU, Han J,
Yocum D. Infliximab dose escalation in patients
with rheumatoid arthritis. Results from the START
trial. Arthritis Rheum 2004;50(Suppl):S185–6.
97. van Vollenhoven RF, Brannemark S, Klareskog L.
Dose escalation of infliximab in clinical practice:
improvements seen may be explained by a
regression-like effect. Ann Rheum Dis 2004;
63:426–30.
98. Stern R, Wolfe F. Infliximab dose and clinical
status: results of 2 studies in 1642 patients with
rheumatoid arthritis. J Rheumatol 2004;31:1538–45.
99. Schiff M, Mease P, Weinblatt M, Moreland L,
Burge D. Randomized control trial of 25 mg vs.
50 mg Enbrel (etanercept) twice weekly in
rheumatoid arthritis (RA) [abstract 1947]. Arthritis
Rheum 2000;43(9 Suppl):S391.
100. Blumenauer B, Judd M, Wells G, Burls A,
Cranney A, Hochberg M, et al. Infliximab for the
treatment of rheumatoid arthritis [review].
Cochrane Database Syst Rev 2002;(3):CD003785.
101. Deeks JJ, Higgins JPT, Altman DG. Analysing and
presenting results. In Higgins JPT, Green S,
editors. Cochrane handbook for systematic reviews for
interventions 4.2.4 [updated March 2005]; Section
8. Chichester: John Wiley & Sons; 2005.
102. Breedveld FC, Kavanaugh AF, Cohen SB,
Pavelka K, van Vollenhoven R, Perez JL, et al. Early
treatment of rheumatoid arthritis (RA) with
adalimumab (HUMIRA ® ) plus methotrexate vs.
adalimumab alone or methotrexate alone. The
PREMIER study [abstract L5]. Arthritis Rheum
2004;50:4096–7.
103. Codreanu C, Combe B, Fiocco U, Gaubitz M,
Geusens PP, Kvien T, et al. Double-blind
comparison of etanercept and sulfasalazine, alone
and combined in active RA patients [abstract
THU0120]. EULAR 2003; 2003.
104. Baumgartner SW, Paulus H, Burch F, Kivitz A,
Dunn M, Kerr D, et al. A study to determine the
safety of etanercept (Enbrel) in patients with
rheumatoid arthritis who have concomitant
© Queen’s Printer and Controller of HMSO 2006. All rights reserved.
Health Technology Assessment 2006; Vol. 10: No. 42
comorbid conditions [abstract 1765]. Arthritis
Rheum 2004;50(9 Suppl):S660–1.
105. Yocum D, Rahman MU, Han C, Bala M, Han J,
Westhovens R. Infliximab rapidly improves all
components of physical function assessed by the
HAQ in patients with rheumatoid arthritis: results
from the START trial [abstract]. Arthritis Rheum
2004;50(9 Suppl):S188–9.
106. Schattenkirchner M, Krüger K, Sander O, Rau R,
Kroot EJ, van Riel PL, et al. Efficacy and
tolerability of weekly subcutaneous injections of
the fully human anti-TNF antibody D2E7 in
patients with rheumatoid arthritis – results of a
Phase I study. Arthritis Rheum 1998;
41(9 Suppl):S57.
107. van Riel P, Taggart A, Sany J, Gaubitz M, Garcia
Lopez A, Korpela M, et al. Clinical efficacy and
safety of the combination of etanercept plus
methotrexate and etanercept alone in the
treatment of rheumatoid arthritis patients with an
inadequate response to methotrexate: the ADORE
study [EULAR 2005 abstract]. Ann Rheum Dis
2005;64(Suppl III):437.
108. Goekoop-Ruiterman YPM, De Vries-Bouwstra JK,
Allaart CF, Van Zeben D, Kerstens PJSM,
Hazes JMW, et al. Clinical and radiological
outcomes of four different treatment strategies in
patients with early rheumatoid arthritis (the BeSt
study): a randomized, controlled trial. Arthritis
Rheum 2005;52:3381–90.
109. Breedveld FC, Weisman MH, Kavanaugh AF,
Cohen SB, Pavelka K, van Vollenhoven R, et al.
The PREMIER study. A multicenter, randomized,
double-blind clinical trial of combination therapy
with adalimumab plus methotrexate versus
methotrexate alone or adalimumab alone in
patients with early, aggressive rheumatoid arthritis
who had not had previous methotrexate treatment.
Arthritis Rheum 2006;54:26–37.
110. van der Heijde D, Klareskog L, Rodriguez-
Valverde V, Codreanu C, Bolosiu H, Melo-Gomes J,
et al. Comparison of etanercept and methotrexate,
alone and combined, in the treatment of
rheumatoid arthritis. Arthritis Rheum 2006;
54:1063–74.
111. Westhovens R, Yocum D, Han J, Berman A,
Strusberg I, Geusens P, et al. The safety of
infliximab, combined with background treatments,
among patients with rheumatoid arthritis and
various comorbidities: a large, randomized,
placebo-controlled trial. Arthritis Rheum 2006;
54:1075–86.
112. Weinblatt ME, Keystone EC, Furst DE,
Moreland LW, Weisman MH, Birbara CA, et al.
Adalimumab, a fully human anti-tumor necrosis
factor alpha monoclonal antibody, for the
treatment of rheumatoid arthritis in patients
taking concomitant methotrexate: the ARMADA
131